Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 6/20 | 0.48 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | F9 | P00740 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25891327 | 1.00 | LPL (0.48) | LPLLIPGSLC6A4CA1CA2 | |
| SCHEMBL24133492 | 0.88 | SLC6A4 (0.38) | LPLLIPGSLC6A4CA1CA2 | |
| SCHEMBL30408614 | 0.88 | SLC6A4 (0.38) | LPLLIPGSLC6A4CA1CA2 | |
| SCHEMBL24133487 | 0.88 | SLC6A4 (0.38) | LPLLIPGSLC6A4CA1CA2 | |
| SCHEMBL26916505 | 0.83 | JAK2 (0.41) | LPLLIPGAAK1 | |
| SCHEMBL29857863 | 0.83 | JAK2 (0.41) | LPLLIPGAAK1 | |
| SCHEMBL26916500 | 0.83 | JAK2 (0.41) | LPLLIPGAAK1 | |
| SCHEMBL25280458 | 0.82 | LPL (0.42) | LPLLIPGSLC6A4CA1CA2 | |
| SCHEMBL30566094 | 0.82 | LPL (0.42) | LPLLIPGSLC6A4CA1CA2 | |
| SCHEMBL25250508 | 0.82 | LPL (0.42) | LPLLIPGSLC6A4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741018-A2 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-05-13 | — | — | EP | disclosed |
| US-12583836-B2 | Sulphonamide compounds | Anaxis Pharma Pty Ltd (AU) | 2026-03-24 | — | — | US | disclosed |
| EP-4168401-B1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-01-07 | — | — | EP | disclosed |
| US-20250074891-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-03-06 | — | — | US | disclosed |
| EP-4452966-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| WO-2023115149-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115149-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| EP-4168401-A1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-04-26 | — | — | EP | disclosed |
| WO-2021253095-A1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021253095-A1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2021-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074891-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | MLKL, RIPK3, CASP9 | LPL 3669/4885LIPG 2631/4885SLC6A4 2435/4885 |
| US-12583836-B2 | Sulphonamide compounds | MLKL, RIPK3, CASP1 | LPL 2832/4885LIPG 2930/4885SLC6A4 1358/4885 |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | MLKL, RIPK3, CASP1 | LPL 3971/4885LIPG 2963/4885SLC6A4 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.